How consultant pharmacist Dr. DeLon Canterbury
helps patients safely go off psychotropic drugs

Wednesday, September 10, 2025
10-11 am PST | 1-2 pm EST | 5-6 pm GMT
Register today! Registration closes noon PST September 8, 2025

Patients who want medically informed guidance in going off prescribed psychotropics often cannot find clinicians with that expertise. In this webinar, DeLon Canterbury, PharmD, BCGP, a pharmacist who has created a private deprescribing practice, will discuss:

Photo of DeLon Canterbury, PharmD, BCGP
DeLon Canterbury, PharmD, BCGP
  • Becoming a pharmacist offering consultation to patients and physicians about deprescribing
  • Helping patients design a taper schedule
  • Communicating with the treating physician (and how this advice is received)
  • Handling customized doses and orders for compounding
  • The success of his approach
  • Case study: Deprescribing benzodiazepine for an 80-year-old woman

A short question-and-answer period will follow the presentation. Note that the speaker cannot advise on individual treatment.

Reserve your place here. Donations are requested to support our webinar series. Registration closes noon PST September 8, 2025. A video of the webinar will be available for those who register but find they cannot attend.

Consulting with the treating physician on individualized tapers

DeLon will explore the technical aspects of customized dosing and the art of creating individualized taper schedules. His methodology for designing these schedules represents years of fostering collaborative relationships with physicians while advocating for patient-centered tapering and individualized dosages.

This addresses a critical gap in protocols for deprescribing psychotropics: a customized prescription must be issued by a clinician licensed to write prescriptions. His insights into navigating the professional dynamics of being a deprescribing consultant will be especially valuable for pharmacists seeking to expand their scope of practice.

He will present a case study of benzodiazepine deprescribing in an 80-year-old woman that illustrates the complexities involved in psychotropic deprescribing. This population presents unique challenges due to age-related pharmacokinetic changes, polypharmacy concerns, and increased vulnerability to withdrawal effects.

An inappropriate antipsychotic endangered his grandmother

DeLon has personal experience in addressing inappropriate psychotropic drug treatment in the elderly. He initially intended to dedicate his career to serving low-income and rural populations throughout North Carolina as a community pharmacist. But a devastating experience with his grandmother, Mildred, redirected his professional focus from traditional community pharmacy to trailblazing.

While he was attending the University of North Carolina Eshelman School of Pharmacy, DeLon’s grandmother Mildred, who had mild dementia, was in an assisted-living facility. For months, the family watched helplessly as Mildred’s cognitive decline accelerated, manifesting in increased wandering, hiding of valuables, and severe memory loss. As it turned out, she had been inappropriately prescribed a sedating antipsychotic. During a medication refill, the community pharmacist pointed out the Black Box warning associated with antipsychotics for dementia patients. The pharmacist “advocated for our family by calling the doctor and having the medicine deprescribed over a few weeks, where Mildred returned to her baseline self,” DeLon has written. “She died my last day of pharmacy school, but lived to see 90 years old because of this pharmacist.”

That was in 2014. This preventable medical error that endangered his grandmother set DeLon on an unusual path: to becoming the “Deprescribing Pharmacist” with a private practice.

A private practice in deprescribing for patients

To provide expert deprescribing consultation for patients, caregivers, and healthcare teams, in 2019 DeLon founded a concierge deprescribing telehealth service, GeriatRx. GeriatRx’s first patient was a 70-year-old woman taking 36 prescriptions involving numerous prescribing cascades, polypharmacy, and duplicate therapies. Due to severe memory loss and oversedation, she had been described as a “walking zombie” by her caregiving daughter.

Working collaboratively with her primary care physician, DeLon strategically tapered her medications down to only 3 medications over time. She was able to remain at home rather than require costly memory care placement, saving the family the substantial cost of a nursing home while allowing the patient to age gracefully in place.

An active member of the US Deprescribing Research Network (USDeN), DeLon recently received a mini-grant in partnership with Duke CERI and AME Zion HEAL for groundbreaking research focused on African-American communities. His current pilot study is the first African-American focused deprescribing initiative using faith-based communities and precision medicine.

Make your reservation before noon PST September 8. If you cannot attend, a video of the webinar will be available later for those on our registration list.

Hyperbolic Tapering Tips: Enablers and Barriers,
with Mark Horowitz, MBBS PhD

Monday, July 28, 2025
10-11 a.m PST  |  1-2 p.m. EST  |  5-6 p.m. GMT
Registration closed noon PST July 26, 2025

Dr. Mark Horowitz
Dr. Mark Horowitz

Hyperbolic tapering — what is it and how do you do it? Find out in this webinar for clinicians.

Psychiatric researcher and clinician Mark Horowitz, MBBS, PhD, originator of the Horowitz-Taylor method for hyperbolic tapering of psychotropics and lead author of the 2024 Maudsley Deprescribing Guidelines for Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs, will present an overview of the facilitators in implementing careful tapering in clinical practice, as well as some barriers.

Mark also will touch upon a few advanced techniques, such as micro-tapering, the art of updosing and reinstatement, and managing protracted withdrawal.

A short question and answer period will follow Mark’s presentation. A video of the webinar will be available for those who register but find they cannot attend.

The Maudsley Deprescribing Guidelines have been endorsed by the UK Royal Pharmaceutical Society and the Royal Australian College of General Practitioners. With this book as a basis, Mark, who is a Clinical Research Fellow in Psychiatry in the NHS, has been commissioned by Health Education England to prepare a teaching module for NHS clinicians on how to safely stop antidepressants.

Mark holds a PhD from the Institute of Psychiatry, Psychology and Neuroscience at King’s College London in the neurobiology of depression and antidepressant action. He is Visiting Lecturer in Psychopharmacology at King’s College London and an Associate Editor of the journal Therapeutic Advances in Psychopharmacology. 

The Maudsley Deprescribing Guidelines
The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs by Mark Horowitz and David M. Taylor

He co-authored the Royal College of Psychiatrists’ guidance on ‘Stopping Antidepressants’ and his work informed the recent NICE guidelines on safe tapering of psychiatric medications, including antidepressants, benzodiazepines and z-drugs. He has worked with the NHS to develop national guidance for safe deprescribing for clinicians. 

Mark has written many papers about safe approaches to tapering psychiatric medications, including publications in The Lancet Psychiatry, JAMA Psychiatry, and Schizophrenia Bulletin.

His own experience of difficulty of coming off psychiatric medications has informed his interest in rational psychopharmacology and deprescribing psychiatric medication. 

If you have registered, we will email a reminder and webinar link shortly before the date of the webinar. Registration closes noon PST July 26, 2025. A video of the webinar will be available for those who register but find they cannot attend. If you have missed registering but are interested in receiving notification of other PDC events, please complete this form.

Bridging to Recovery While Deprescribing Psychiatric Drugs,
with Anders Sørensen, PhD

Friday, June 27, 2025
10-11 a.m PST  |  1-2 p.m. EST  |  5-6 p.m. GMT
Register today! Registration closes noon PST June 26, 2025

When psychiatric drug treatment comes to an end, how may a clinician minimize the risk of withdrawal or relapse while deprescribing? In this webinar presented by the Psychotropic Deprescribing Council, Danish psychologist and researcher Anders Sørensen, PhD offers his views on this important clinical skill, discussing his work in helping patients find their ways through tapering off antidepressants and psychiatric drugs to a new life supported by  psychotherapy.

A short question and answer period will follow Anders’s presentation. A video of the webinar will be available for those who register but find they cannot attend. Please register for this webinar today.

Early in his training, Anders observed that the masking effects of psychiatric drugs often interfered with his clients’ abilities to address the root causes of their emotional distress and that these drugs could be very difficult to stop. He then obtained his PhD in psychiatric drug tapering and now specializes in advising people how to come off psychiatric drugs through gradual, hyperbolic tapering while providing psychotherapy to enable them to stay off.

Anders Sørensen, PhD

Anders’s most recent work is a book, Crossing Zero – The Art and Science of Coming Off and Staying Off Psychiatric Drugs, to be published this summer, which incorporates the concept of recovery into psychiatric drug treatment. The first part of the book provides a clear, thoughtful interpretation of  how psychiatric drugs do and do not work. In the second part, Anders explains the science of hyperbolic tapering and step-by-step methods to minimize the risk of withdrawal symptoms. In the last part, Life beyond Medication, Anders explores psychotherapeutic approaches to overcoming the difficult thoughts, behaviors, and emotions that underlie our various mental health diagnostic labels.

Anders’s scientific research includes systematic reviews such as Sørensen, et al. (2022). Description of antidepressant withdrawal symptoms in clinical practice guidelines on depression: A systematic review and Sørensen, et al. (2021). The relationship between dose and serotonin transporter occupancy of antidepressants—A systematic review. In addition to his writing, research, and clinical practice, Anders shares information about psychiatric drug tapering with the general public through social media, interviews, articles, and his popular YouTube channel, @AndersSorensen.

Register today! We will email a reminder and webinar link shortly before the date of the webinar. Registration closes noon PST June 26, 2025. If you cannot attend but are interested in receiving notification of other PDC events, please complete this form.